Holen Sie sich die Stockscreener-App
11.45
1.24%
0.14
Handel nachbörslich:
11.50
0.05
+0.44%
Telix Pharmaceuticals Ltd Adr Aktie (TLX) Neueste Nachrichten
Why is Telix Pharmaceuticals stock rallying today? By Investing.com - Investing.com Canada
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse - GlobeNewswire Inc.
Telix Pharmaceuticals stock price target maintained at $20 by H.C. Wainwright - Investing.com Australia
ASX biotech expands diagnostics portfolio after FDA approval - Morningstar Australia
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock hits 52-week high at 12.48 USD - investing.com
Two New York conferences will include Telix presentations - Stock Titan
Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway - finance.yahoo.com
Telix Pharmaceuticals stock jumps on trial completion, FDA path By Investing.com - Investing.com Nigeria
Telix Pharmaceuticals stock jumps on trial completion, FDA path - Investing.com
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on trial completion - Investing.com UK
Dell, Gitlab surge 11-14% on strong Q2 results; Sirius XM rises - scanx.trade
Up to 75% of prostate biopsies are negative. Telix enrolled 350 patients. - Stock Titan
Earnings call transcript: Telix H1 2026 profit jumps as guidance holds - Investing.com
Telix R&D Day to Feature Pipeline Updates and Outside Experts - Stock Titan
Telix Schedules Aug. 20 Webcast for Half-Year Results - Stock Titan
Study Tests Imaging to Select Patients for Telix Prostate Therapy - Stock Titan
ETFs Investing in Telix Pharmaceuticals Limited Sponsored ADR Stocks - TradingView
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals (ASX:TLX) Targets More Than US$1 Billion in Revenue and Other Income After Quarterly Revenue Jumps 21% - Kalkine
Telix Starts Phase 3 Targeted Radiation Study for Kidney Cancer - Stock Titan
Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer - Stock Titan
H.C. Wainwright reiterates Telix Pharmaceuticals stock rating on FDA trial progress - Investing.com
Telix Pharmaceuticals (ASX:TLX): The Nuclear Medicine Company Attracting Significant Investor Attention - Kalkine
Why Is Telix Pharmaceuticals (ASX:TLX) on Investors' Radar Despite a 30% One-Year Decline? - Kalkine
FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design - Stock Titan
Telix Pharmaceuticals (ASX:TLX) in Focus After Positive U.S. Regulatory Update - Kalkine
Telix clears FDA protocol review for prostate cancer trial expansion - Stock Titan
Telix Pharmaceuticals Limited Sponsored ADR Actuals & Estimates (NASDAQ:TLX) - TradingView
Telix webinar spotlights glioblastoma care and theranostics next week - Stock Titan
ASX Healthcare Sector Rally: CSL, ResMed and Telix Advance on Broad Market Strength - Kalkine
AI-enhanced cancer scans: Telix and United Imaging team up on theranostics - Stock Titan
Prostate cancer trial: Telix therapy shows acceptable safety in combo treatment - stocktitan.net
Telix CEO lines up back-to-back investor talks in Chicago and New York - stocktitan.net
TLX - Finviz
TLX SEC FilingsTelix Pharmaceuticals Ltd ADR 10-K, 10-Q, 8-K Forms - Stock Titan
Telix Pharmaceuticals Ltd stock (AU000000TLX2): FDA filing advances - Ad-hoc-news.de
Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K - Stock Titan
Telix Pharmaceuticals (TLX) director Form 3 shows no share trades - Stock Titan
Telix Pharmaceuticals (TLX) director Jellison files initial Form 3 ownership - Stock Titan
Maria Rivas joins Telix Pharmaceuticals (TLX) board and files initial Form 3 - Stock Titan
Prostate cancer imaging tie-up aims to cut incontinence, impotence risks - Stock Titan
Can Telix Pharmaceuticals (ASX:TLX) Regain Momentum Ahead of Key FDA Decision? - Kalkine
Telix (TLX) CEO boosts indirect stake with 67,935-share open-market buy - Stock Titan
Kidney cancer scan showed 98% positive predictive value in analysis - stocktitan.net
Europe begins 210-day review of Telix brain cancer imaging candidate - Stock Titan
Telix reports dosimetry data for prostate cancer therapy candidate - Investing.com
Wedge UpStock ScreenerCharts - Finviz
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):